

NEWS EXPRESS	January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:41:56 ON 04 FEB 2003

=> file caplus uspatful europatful japiro medline biosis embase  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 1.47 1.47

FILE 'CAPLUS' ENTERED AT 12:46:04 ON 04 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:46:04 ON 04 FEB 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 12:46:04 ON 04 FEB 2003  
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 12:46:04 ON 04 FEB 2003  
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 12:46:04 ON 04 FEB 2003

FILE 'BIOSIS' ENTERED AT 12:46:04 ON 04 FEB 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 12:46:04 ON 04 FEB 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s inhal? and (powder or particulat? or pellet)  
L1 32803 INHAL? AND (POWDER OR PARTICULAT? OR PELLET)

=> s 11 and tiotropium  
L2 117 L1 AND TIOTROPIUM

=> s 12 and (average particle size)  
L3 12 L2 AND (AVERAGE PARTICLE SIZE)

=> s 13 and (chloride or bromide or iodide methanesulphonate or paratoluenesulphonate or (methyl sulphate))

L4 12 L3 AND (CHLORIDE OR BROMIDE OR IODIDE METHANESULPHONATE OR PARATOLUENESULPHONATE OR (METHYL SULPHATE))

=> d 14 1-12 ibib abs

L4 ANSWER 1 OF 12 USPATFULL

ACCESSION NUMBER: 2003:24176 USPATFULL  
TITLE: Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics  
INVENTOR(S): Meade, Christopher J.M., Bingen, GERMANY, FEDERAL REPUBLIC OF  
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF  
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC OF  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018019	A1	20030123
APPLICATION INFO.:	US 2002-173194	A1	20020617 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-130371	20010623
	US 2001-304148P	20010710 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1170	
AB	The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases.	

L4 ANSWER 2 OF 12 USPATFULL

ACCESSION NUMBER: 2002:338027 USPATFULL  
TITLE: Compounds for treating inflammatory diseases  
INVENTOR(S): Disse, Bernd, Mainz, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193394	A1	20021219
APPLICATION INFO.:	US 2002-96810	A1	20020313 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-111843	20010313
	US 2001-281876P	20010405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	661	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of (1.alpha..2.beta.,4.beta..5.alpha..7  
.beta.)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-  
azoniatricyclo[3.3.1.0.sup.2,4] nonane salts for preparing a  
pharmaceutical composition for the prevention and treatment of diseases  
associated with inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 12 USPATFULL

ACCESSION NUMBER: 2002:338026 USPATFULL  
TITLE: Pharmaceutical compositions based on anticholinergics  
and PDE-IV inhibitors

INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF  
Meade, Christopher J. M., Bingen, GERMANY, FEDERAL  
REPUBLIC OF  
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC  
OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193393	A1	20021219
APPLICATION INFO.:	US 2002-93240	A1	20020307 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-110772	20010307
	US 2001-281857P	20010405 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,  
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 13  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 1018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based  
on anticholinergics and PDE-IV inhibitors, processes for preparing them  
and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 12 USPATFULL

ACCESSION NUMBER: 2002:338025 USPATFULL  
TITLE: Pharmaceutical compositions based on **tiotropium**  
salts of salts of salmeterol  
INVENTOR(S): Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL  
REPUBLIC OF  
Nagel, Juergen, Bad Kreuznach, GERMANY, FEDERAL  
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193392	A1	20021219
APPLICATION INFO.:	US 2001-54567	A1	20011113 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10056104	20001113
	US 2000-251603P	20001206 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,  
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 46

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition, comprising: (a) a **tiotropium** salt (1); and (b) a salmeterol salt (2), optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient, and methods of treating respiratory diseases using such a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 12 USPATFULL

ACCESSION NUMBER: 2002:323179 USPATFULL

TITLE: Pharmaceutical compositions based on anticholinergics and endothelin antagonists

INVENTOR(S): Meade, Christopher J. M., Bingen, GERMANY, FEDERAL REPUBLIC OF  
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF  
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183347	A1	20021205
APPLICATION INFO.:	US 2002-100659	A1	20020318 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-113366	20010320
	US 2001-281874P	20010405 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,  
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on anticholinergics and endothelin antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 12 USPATFULL

ACCESSION NUMBER: 2002:323126 USPATFULL

TITLE: Pharmaceutical compositions based on anticholinergics and corticosteroids

INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF  
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC OF  
Meade, Christopher John Montague, Bingen, GERMANY,  
FEDERAL REPUBLIC OF  
Reichl, Richard, Gau-Algesheim, GERMANY, FEDERAL  
REPUBLIC OF

Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL  
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183292	A1	20021205
APPLICATION INFO.:	US 2001-86145	A1	20011019 (10)

	NUMBER	DATE	-
PRIORITY INFORMATION:	DE 2000-10054042	20001031	
	DE 2000-10062712	20001215	
	US 2000-257220P	20001221 (60)	
	US 2000-253613P	20001128 (60)	

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,  
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 66

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising an anticholinergic and a steroid, optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the steroid optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 12 USPATFULL

ACCESSION NUMBER: 2002:301636 USPATFULL

TITLE: Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists

INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF  
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC OF  
Meade, Christopher J. M., Bingen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169181	A1	20021114
APPLICATION INFO.:	US 2002-92116	A1	20020306 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-DE111058	20010308
	US 2001-281653P	20010405 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,  
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 1338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on anticholinergics and NK<sub>1</sub>-receptor antagonists, processes for

preparing them and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 12 USPATFULL  
ACCESSION NUMBER: 2002:273413 USPATFULL  
TITLE: Pharmaceutical compositions containing  
tiotropium salts and antihistamines and their  
use  
INVENTOR(S): Pairet, Michel, Stromberg, GERMANY, FEDERAL REPUBLIC OF  
Pieper, Michael P., Ingelheim, GERMANY, FEDERAL  
REPUBLIC OF  
Meade, Christopher John Montague, Bingen, GERMANY,  
FEDERAL REPUBLIC OF  
Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL  
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151541	A1	20021017
APPLICATION INFO.:	US 2001-7182	A1	20011019 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10054042	20001031
	DE 2001-138272	20010810
	US 2000-253613P	20001128 (60)
	US 2001-314599P	20010824 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEURY ROAD,  
P. O. BOX 368, RIDGEFIELD, CT, 06877  
NUMBER OF CLAIMS: 58  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 1074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising a tiotropium salt; and  
an antihistamine, optionally together with a pharmaceutically acceptable  
excipient, the tiotropium salt and the antihistamine  
optionally in the form of their enantiomers, mixtures of their  
enantiomers, their racemates, their solvates, or their hydrates,  
processes for preparing them, and their use in the treatment of  
respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 12 USPATFULL  
ACCESSION NUMBER: 2002:227675 USPATFULL  
TITLE: Solid peptide preparations for inhalation and  
their preparation  
INVENTOR(S): Lizio, Rosario, Buttelborn, GERMANY, FEDERAL REPUBLIC  
OF  
Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF  
Sarlikiotis, Werner, Peania, GREECE  
Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL  
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122826	A1	20020905

APPLICATION INFO.: US 2001-944060 A1 20010831 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10043509	20000901
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Goodwin Procter L.L.P., 599 Lexington Avenue, 40th floor, New York, NY, 10022	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	764	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to solid pharmaceutical preparations, in particular for **inhalatory** administration in mammals, their preparation and their use such as, for example, in **powder inhalers**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 12 USPATFULL  
ACCESSION NUMBER: 2002:227622 USPATFULL  
TITLE: Pharmaceutical compositions based on anticholinergics and dopamine agonists  
INVENTOR(S): Pairet, Michel, Stromberg, GERMANY, FEDERAL REPUBLIC OF Pieper, Michael P., Ingelheim, GERMANY, FEDERAL REPUBLIC OF Montague Meade, Christopher J., Bingen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122773	A1	20020905
APPLICATION INFO.:	US 2001-27662	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-DE10063957	20001220
	US 2000-257221P	20001221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1016	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on anticholinergics and dopamine agonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 12 USPATFULL  
ACCESSION NUMBER: 2002:205842 USPATFULL  
TITLE: Inhalable powder containing **tiotropium**  
INVENTOR(S): Bechtold-Peters, Karoline, Biberach, GERMANY, FEDERAL REPUBLIC OF Walz, Michael, Bingen, GERMANY, FEDERAL REPUBLIC OF

Boeck, Georg, Mainz, GERMANY, FEDERAL REPUBLIC OF  
Doerr, Rolf, Ober-Olm, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110529	A1	20020815
APPLICATION INFO.:	US 2001-975418	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-DE10050635	20001012
	US 2000-252683P	20001122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	561	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to powdered preparations containing **tiotropium** for **inhalation**, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 12 USPATFULL  
ACCESSION NUMBER: 2002:198239 USPATFULL  
TITLE: Process for preparing **powder** formulations  
INVENTOR(S): Walz, Michael, Bingen, GERMANY, FEDERAL REPUBLIC OF  
Boeck, Georg, Mainz, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106332	A1	20020808
APPLICATION INFO.:	US 2001-977911	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-DE10050635	20001012
	DE 2001-DE138022	20010810
	US 2000-252683P	20001122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	650	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a new process for producing powdered preparations for **inhalation**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau153cxa

**PASSWORD :**

TERMINAL. (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004

=> le caplus uspatful europatful japiro medline biosis embase  
LE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).

=> file caplus uspatful europatful japiro medline biosis embase  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 16:10:45 ON 10 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'MEDLINE' ENTERED AT 16:10:45 ON 10 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))  
L1 60 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s 11 and (particle# or particulate#)  
L2 29 L1 AND (PARTICLE# OR PARTICULATE#)

=> s 12 and powder?  
L3 19 L2 AND POWDER?

=> s l3 and capsule?  
L4 13 L3 AND CAPSULE?

=> s 14 and (COPD or asthma)  
L5 5 L4 AND (COPD OR ASTHMA)

=> s 15 and (method or process) and (making or preparation or manufacture)  
6 FILES SEARCHED...

L6 2 L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MANUFACTURE)

=> d 16 1-2 IBIB ABA

'ABA' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ABS

NO VALID FORMATS ENTERED FOR FILE 'EUROPATFULL'

In a multifile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):AB

L6 ANSWER 1 OF 2 USPATFULL on STN

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β.sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> S

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):L6 ibib ab  
MISSING OPERATOR L6 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d 16 1-2 IBIB AB

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Peselev, Elli

LEGAL REPRESENTATIVE: Levi-Minzi, Simona A.

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

**AB** The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β.sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS  
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.  
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.  
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.  
**INVENTOR(S):** MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;  
YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP  
**PATENT ASSIGNEE(S):** ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP  
**PATENT ASSIGNEE NO:** 435424  
**AGENT:** Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675 Muenchen, DE  
**AGENT NUMBER:** 100401  
**OTHER SOURCE:** MEPA2004039 EP 1417975 A1 0322  
**SOURCE:** Wila-EPZ-2004-H20-T1b  
**DOCUMENT TYPE:** Patent  
**LANGUAGE:** Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch  
**DESIGNATED STATES:** R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI  
**PATENT INFO.PUB.TYPE:** EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)  
**PATENT INFORMATION:**

PATENT NO	KIND DATE
EP 1417975	A1 20040512
'OFFENLEGUNGS' DATE:	20040512
APPLICATION INFO.:	EP 2002-747707
	20020722

PRIORITY APPLN. INFO.: JP 2001-2001222148 20010723  
                   JP 2001-2001239895 20010807  
                   JP 2002-2002056449 20020301  
 RELATED DOC. INFO.: WO 02-JP7385 020722 INTAKZ  
                   WO 2003009872 030206 INTPNR

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'  
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1       60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI  
 L2       29 S L1 AND (PARTICLE# OR PARTICULATE#)  
 L3       19 S L2 AND POWDER?  
 L4       13 S L3 AND CAPSULE?  
 L5       5 S L4 AND (COPD OR ASTHMA)  
 L6       2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

=> d 15 1-5

L5       ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN      2003:757705 CAPLUS  
 DN      139:265796  
 TI      Preparation of micronized crystalline tiotropium bromide monohydrate and formulation as inhalant to treat asthma and COPD  
 IN      Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef Friedrich; Walz, Michael  
 PA      Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany  
 SO      PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DT      Patent  
 LA      German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10212264	A1	20031002	DE 2002-10212264	20020320
	US 2004002510	A1	20040101	US 2003-385175	20030310
PRAI	DE 2002-10212264	A	20020320		
	US 2002-413129P	P	20020924		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:368320 CAPLUS  
DN 136:374855  
TI Inhalant compositions containing tiotropium salts and salmeterol salts  
IN Schmelzer, Christel; Nagel, Juergen  
PA Boehringer Ingelheim Pharma K.-G., Germany  
SO PCT Int. Appl., 36 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512
PRAI DE 2000-10056104	A	20001113		
US 2000-251603P	P	20001206		
WO 2001-EP12962	W	20011109		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:689613 CAPLUS  
DN 136:390861  
TI Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity  
AU Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.  
CS Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA  
SO Journal of Aerosol Medicine (2001), 14(3), 309-315  
CODEN: JAEMEP; ISSN: 0894-2684  
PB Mary Ann Liebert, Inc.  
DT Journal  
LA English  
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 USPATFULL on STN  
AN 2001:75378 USPATFULL  
TI Methods and compositions for the prevention of tolerance to medications  
IN Ahmed, Tahir, Coral Gables, FL, United States

PA Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S.  
 corporation)  
 PI US 6235725 B1 20010522  
 AI US 1999-362540 19990728 (9)  
 PRAI US 1998-106507P 19981030 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 985  
 INCL INCLM: 514/056.000  
 INCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000  
 NCL NCLM: 514/056.000  
 NCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000  
 IC [7]  
 ICM: A61K031-70  
 EXF 514/53; 514/54; 514/56; 514/653; 514/826; 514/23  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1417975 EUROPATFULL ED 20040513 EW 200420 FS OS  
 TIEN REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE  
 ACTIVE INGREDIENT.  
 TIDE MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND  
 EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.  
 TIFR MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF  
 DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.  
 IN MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai  
 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;  
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai  
 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai  
 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP  
 PA ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku,  
 Osaka-shi, Osaka 541-8526, JP  
 SO Wila-EPZ-2004-H20-T1b  
 DS R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR;  
 R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR;  
 R AL; R LT; R LV; R MK; R RO; R SI  
 PIT EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale Anmeldung)  
 PI EP 1417975 A1 20040512  
 OD 20040512  
 AI EP 2002-747707 20020722  
 PRAI JP 2001-2001222148 20010723  
 JP 2001-2001239895 20010807  
 JP 2002-2002056449 20020301  
 RLI WO 02-JP7385 020722 INTAKZ  
 WO 2003009872 030206 INTPNR  
 IC ICM A61K045-00  
 ICS A61K031-559 C07D207-24 C07D207-27 C07D263-24  
 C07C405-00 A61P019-08 A61P019-10

=> FIL STNGUIDE  
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

65.21

65.42

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jun 4, 2004 (20040604/UP).

=> file caplus uspatfull japiro europaftul biosis embase medline  
'EUROPAFTUL' IS NOT A VALID FILE NAME  
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files  
that are available. If you have requested multiple files, you can  
specify a corrected file name or you can enter "IGNORE" to continue  
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):europatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.66	66.08

FILE 'CAPLUS' ENTERED AT 16:28:44 ON 10 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'EUROPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:28:44 ON 10 JUN 2004

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'  
ENTERED AT 16:10:45 ON 10 JUN 2004  
L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI  
L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)  
L3 19 S L2 AND POWDER?  
L4 13 S L3 AND CAPSULE?  
L5 5 S L4 AND (COPD OR ASTHMA)  
L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'  
ENTERED AT 16:28:44 ON 10 JUN 2004

=> s 14 1-13

MISSING OPERATOR L4 1-13

The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> d 14 1-13 ibib abs

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2003:757705 CAPLUS  
DOCUMENT NUMBER: 139:265796  
TITLE: Preparation of micronized crystalline tiotropium bromide monohydrate and formulation as inhalant to treat asthma and COPD  
INVENTOR(S): Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef Friedrich; Walz, Michael  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany  
SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10212264	A1	20031002	DE 2002-10212264	20020320
US 2004002510	A1	20040101	US 2003-385175	20030310

PRIORITY APPLN. INFO.: DE 2002-10212264 A 20020320  
US 2002-413129P P 20020924

AB The invention relates to a micronized crystalline ( $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$ ,  $\epsilon$ -[ $\alpha$ ]-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 $2$ . $4$ ]nonane bromide, methods for the production thereof, and the use thereof for producing a medicament, particularly for producing a medicament having an anticholinergic effect. The preparation of tiotropium bromide monohydrate microcrystals includes the solution of tiotropium bromide in water, heating, clarification with active carbon, filtration and slow crystallization followed

by micronization in an air jet mill under nitrogen atmospheric and exposing the micronized crystals to water vapor. Parameters of the monocline crystals are given. Micronized crystalline tiotropium bromide monohydrate is formulated to encapsulated inhalation powder and used to treat asthma and COPD. Thus inhalation capsules contained (mg): micronized tiotropium bromide 0.0225; lactose monohydrate (200 M) 5.2025; lactose monohydrate (5  $\mu$ m) 0.2750; hard gelatin capsules 49.0.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:889143 CAPLUS  
DOCUMENT NUMBER: 137:358198  
TITLE: Stable powder inhalation dosage formulation  
INVENTOR(S): Etzler, Frank M.  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA  
SOURCE: U.S., 6 pp.

CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482429	B1	20021119	US 2001-885349	20010620
WO 2003000240	A2	20030103	WO 2002-US18406	20020611
WO 2003000240	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1401409	A2	20040331	EP 2002-732063	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-885349	A 20010620
			WO 2002-US18406	W 20020611

AB An insufflation for the administration of a drug, e.g., ipratropium bromide, albuterol sulfate or **tiotropium bromide**, into a body cavity is described where the carrier for the drug is a finely divided powder selected from the group consisting of myoinositol, mannitol and cellobiose. For example, the cellobiose blend with ipratropium bromide which was inhaled from capsules into Aerobreather at 20, 40 and 60 L/min has a lower mean particle size than the lactose blend, which is the opposite of the particle sizing results from the Aerosizer. The peaks of the distributions for the cellobiose blend were shifted to lower particle sizes than the lactose blend at all inhalation rates. The difference could reflect differences in adhesion strength, particle size distribution or size selection of retained particles.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:695761 CAPLUS  
 DOCUMENT NUMBER: 137:237718  
 TITLE: Inhalant compositions containing anticholinergics and PDE IV inhibitors  
 INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel; Pieper, Michael Paul  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069945	A2	20020912	WO 2002-EP1988	20020226
WO 2002069945	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
 TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 DE 10110772 A1 20020912 DE 2001-10110772 20010307  
 EP 1372649 A2 20040102 EP 2002-727329 20020226  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 PRIORITY APPLN. INFO.: DE 2001-10110772 A 20010307  
 WO 2002-EP1988 W 20020226

OTHER SOURCE(S): MARPAT 137:237718

AB The invention relates to drug compns. based on anticholinergics and PDE IV inhibitors, to methods for their production, and to their use as inhalants for the treatment of respiratory tract diseases. Thus an inhalation powder was composed of capsules that contained ( $\mu$ g/capsule): tiotropium bromide 21.7; AWD-12-281 200; lactose 4778.3.

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:487380 CAPLUS  
 DOCUMENT NUMBER: 137:68157  
 TITLE: Inhalant compositions containing anticholinergics and dopamine agonists  
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049624	A2	20020627	WO 2001-EP14568	20011212
WO 2002049624	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10063957	A1	20020627	DE 2000-10063957	20001220
AU 2002035767	A5	20020701	AU 2002-35767	20011212
EP 1345626	A2	20030924	EP 2001-985868	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004516264	T2	20040603	JP 2002-550966	20011212
US 2002122773	A1	20020905	US 2001-27662	20011220
PRIORITY APPLN. INFO.:			DE 2000-10063957 A	20001220
			US 2000-257221P P	20001221
			WO 2001-EP14568 W	20011212

AB The invention relates to novel pharmaceutical compns. based on anticholinergic agents and dopamine agonists, a method for the production of the compns. and the use of the same for the treatment of respiratory tract diseases. Thus an inhalation powder contained per capsule ( $\mu$ g): tiotropium bromide 21.7; viozan 270; lactose 4708.3.

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:465799 CAPLUS  
 DOCUMENT NUMBER: 137:37667  
 TITLE: Inhalant compositions containing  
 anticholinergics and ciclesonide corticosteroid  
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,  
 Christopher John Montague  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047668	A2	20020620	WO 2001-EP14579	20011212
WO 2002047668	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002031691	A5	20020624	AU 2002-31691	20011212
EP 1349549	A2	20031008	EP 2001-991827	20011212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515528	T2	20040527	JP 2002-549242	20011212
PRIORITY APPLN. INFO.:			DE 2000-10062712 A	20001215
			DE 2000-10054042 A	20001031
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			WO 2001-EP14579 W	20011212

AB The invention relates to novel medicament compns. based on  
 anticholinesterase drugs and on ST-126, to methods for their production, and  
 to their use in treating respiratory tract diseases. Thus an inhalation  
 powder contained per capsule ( $\mu$ g): tiotropium  
 bromide x H<sub>2</sub>O 22.5; ciclesonide 250; lactose 4727.5.

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:465798 CAPLUS  
 DOCUMENT NUMBER: 137:52368  
 TITLE: Inhalant compositions containing  
 anticholinergics and ST-126 corticosteroid  
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,  
 Christopher John Montague  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047667	A2	20020620	WO 2001-EP14567	20011212
WO 2002047667	A3	20021024		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
 TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 DE 10062712 A1 20020620 DE 2000-10062712 20001215  
 US 2002183292 A1 20021205 US 2001-86145 20011019  
 AU 2002024926 A5 20020624 AU 2002-24926 20011212  
 PRIORITY APPLN. INFO.: DE 2000-10062712 A 20001215  
 DE 2000-10054042 A 20001031  
 US 2000-253613P P 20001128  
 US 2000-257220P P 20001221  
 WO 2001-EP14567 W 20011212

**AB** The invention relates to novel medicament compns. based on anticholinesterase drugs and on ST-126 corticosteroid, to methods for their production, and to their use in treating respiratory tract diseases. Thus an inhalation powder contained per capsule ( $\mu\text{g}$ ): tiotropium bromide x H<sub>2</sub>O 22.5; ST-126 250; lactose 4727.5.

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:368320 CAPLUS  
 DOCUMENT NUMBER: 136:374855  
 TITLE: Inhalant compositions containing tiotropium salts and salmeterol salts  
 INVENTOR(S): Schmelzer, Christel; Nagel, Juergen  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512
PRIORITY APPLN. INFO.:			DE 2000-10056104 A	20001113
			US 2000-251603P P	20001206
			WO 2001-EP12962 W	20011109

**AB** The invention relates to novel drug compns. based on tiotropium

salts and on salmeterol salts, a method for their production and their use for treating respiratory conditions. Thus an inhalation powder contained per capsule ( $\mu$ g): **tiotropium bromide** 10.8; salmeterol x 1/2 H<sub>2</sub>SO<sub>4</sub> 27.9; Lactose 4961.3.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:353268 CAPLUS  
DOCUMENT NUMBER: 136:374832  
TITLE: Inhalant compositions containing anticholinergics and corticosteroids  
INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Reichl, Richard; Schmelzer, Christel  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
SOURCE: PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036106	A2	20020510	WO 2001-EP12511	20011023
WO 2002036106	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002151541	A1	20021017	US 2001-7182	20011019
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002010575	A5	20020515	AU 2002-10575	20011023
EP 1333830	A2	20030813	EP 2001-978463	20011023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004512359	T2	20040422	JP 2002-538918	20011023
US 2002137764	A1	20020926	US 2001-40196	20011025
US 2003181478	A1	20030925	US 2003-395777	20030324
PRIORITY APPLN. INFO.:			DE 2000-10054042 A	20001031
			DE 2000-10062712 A	20001215
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			DE 2001-10138272 A	20010810
			US 2001-314599P P	20010824
			WO 2001-EP12511 W	20011023
			US 2001-40196 B1	20011025

AB The invention relates to novel drug compns. based on anticholinergics and corticosteroids, a method for their production and their use for treating respiratory conditions. Thus an inhalation powder contained per capsule ( $\mu$ g): **tiotropium bromide** 21.7; budesonide 200; Lactose 4778.3.

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2001:689613 CAPLUS  
DOCUMENT NUMBER: 136:390861  
TITLE: Effective delivery of particles with the HandiHaler dry powder inhalation system over

a range of chronic obstructive pulmonary disease severity

AUTHOR(S): Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.

CORPORATE SOURCE: Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA

SOURCE: Journal of Aerosol Medicine (2001), 14(3), 309-315

CODEN: JAEMEP; ISSN: 0894-2684

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The HandiHaler is a dry powder breath activated inhaler system developed for inhalation therapy for patients with airway disease. Its operation is based on the evacuation of powder from a pierced capsule. We sought to document the inspiratory flow rates attained by patients inspiring through the HandiHaler with various degrees of airflow limitation. Subjects with stable chronic obstructive pulmonary disease (COPD) were the study's population. An in vitro study of fine particle dose was conducted using an Andersen Cascade Impactor to assess medication delivery at low inspiratory flow rates. Subsequently, an in vivo study was conducted to determine inspiratory flow rates in patients with COPD as measured through a pneumotach with a custom coupler device with and without the HandiHaler. Patients were classified into three approx. equal groups of spirometric severity ranging from mild (46-65% predicted normal forced expiratory volume in 1 s [FEV1]), to moderate (28-45%) to severe (<27%). The in vitro study indicated delivery of medication at flow rates as low as 20 L/min. Twenty-six men completed the in vivo study (age 66.9±10.9 yr, FEV1 = 1.02±0.451.). The median peak inspiratory flow rates attained in the mild (n = 8), moderate (n = 10), and severe (n = 8) categories were 45, 45.6, and 35.4 L/min resp. The min. peak inspiratory flow rates in the three groups were 28.2, 21.6 and 20.4 L/min. The HandiHaler device effectively delivers particles to the lung over a wide range of airflow limitation in patients with COPD.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators.

More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to  $\beta$ .<sub>2</sub>-adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2001:67205 USPATFULL  
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules  
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States  
Saim, Said, New Milford, CT, United States  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS  
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.  
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.  
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.  
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co.,

Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun,  
 Osaka 618-8585, JP;  
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co.,  
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,  
 Osaka 618-8585, JP;  
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co.,  
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,  
 Osaka 618-8585, JP;  
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co.,  
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,  
 Osaka 618-8585, JP  
**PATENT ASSIGNEE(S) :** ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome,  
 Chuo-ku, Osaka-shi, Osaka 541-8526, JP  
**PATENT ASSIGNEE NO:** 435424  
**AGENT:** Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675  
 Muenchen, DE  
**AGENT NUMBER:** 100401  
**OTHER SOURCE:** MEPA2004039 EP 1417975 A1 0322  
**SOURCE:** Wila-EPZ-2004-H20-T1b  
**DOCUMENT TYPE:** Patent  
**LANGUAGE:** Anmeldung in Japanisch; Veroeffentlichung in Englisch;  
 Verfahren in Englisch  
**DESIGNATED STATES:** R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R  
 ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R  
 MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R  
 MK; R RO; R SI  
**PATENT INFO. PUB. TYPE:** EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale  
 Anmeldung)  
**PATENT INFORMATION:**

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1417975	A1 20040512 20040512
APPLICATION INFO.:	EP 2002-747707	20020722
PRIORITY APPLN. INFO.:	JP 2001-2001222148 JP 2001-2001239895 JP 2002-2002056449	20010723 20010807 20020301
RELATED DOC. INFO.:	WO 02-JP7385 WO 2003009872	020722 INTAKZ 030206 INTPNR

L4 ANSWER 13 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

**PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET**

**ACCESSION NUMBER:** 1391200 EUROPATFULL EW 200409 FS OS  
**TITLE:** DRUG PREPARATIONS.  
 ARZNEIMITTEL.  
 PREPARATIONS DE MEDICAMENTS.  
**INVENTOR(S) :** ONUKI, Yoichi, 2-31-7, Nakadai, Narita-shi, Chiba  
 286-0015, JP;  
 OKADA, Minoru, 4-7-20, Kioroshihigashi, Inzai-shi, Chiba  
 270-1323, JP;  
 SAKAI, Hirotaka, 1-20-6, Yotsukaido, Yotsukaido-shi,  
 Chiba 284-0005, JP;  
 KANBE, Hideyoshi, 2-21-8, Mama, Ichikawa-shi, Chiba  
 272-0826, JP;  
 MIZUNO, Hiroyuki, 1-24-19, Hiyoshidai, Tomisato-machi,  
 Inba-gun, Chiba 286-0201, JP;  
 IMAMORI, Katsumi, 2521-86, Shimoshizushinden,  
 Yotsukaido-shi, Chiba 284-0006, JP  
**PATENT ASSIGNEE(S) :** SSP Co., Ltd., 12-4, Nihonbashi-hamacho 2-chome,  
 Chuo-ku, Tokyo 103-8481, JP  
**PATENT ASSIGNEE NO:** 2557581  
**AGENT:** Hartz, Nikolai, Waechtershaeuser & Hartz,  
 Patentanwaelte, Weinstrasse 8, 80333 Muenchen, DE

AGENT NUMBER: 85663  
 OTHER SOURCE: MEPA2004017 EP 1391200 A1 0014  
 SOURCE: Wila-EPZ-2004-H09-T1b  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;  
 Verfahren in Englisch  
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R  
 GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R  
 SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI  
 PATENT INFO. PUB. TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale  
 Anmeldung)  
 PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1391200	A1 20040225 20040225
APPLICATION INFO.:	EP 2002-726486	20020524
PRIORITY APPLN. INFO.:	JP 2001-2001156853	20010525
RELATED DOC. INFO.:	WO 200JP2005041	020524 INTAKZ
	WO 2002096405	021205 INTPNR

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'  
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1	60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2	29 S L1 AND (PARTICLE# OR PARTICULATE#)
L3	19 S L2 AND POWDER?
L4	13 S L3 AND CAPSULE?
L5	5 S L4 AND (COPD OR ASTHMA)
L6	2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'  
 ENTERED AT 16:28:44 ON 10 JUN 2004

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	63.51	129.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'USPATFULL' ENTERED AT 16:45:49 ON 10 JUN 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Jun 2004 (20040610/PD)  
 FILE LAST UPDATED: 10 Jun 2004 (20040610/ED)  
 HIGHEST GRANTED PATENT NUMBER: US6748598  
 HIGHEST APPLICATION PUBLICATION NUMBER: US2004111778  
 CA INDEXING IS CURRENT THROUGH 10 Jun 2004 (20040610/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Jun 2004 (20040610/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
 >>> original, i.e., the earliest published granted patents or <<<  
 >>> applications. USPAT2 contains full text of the latest US <<<  
 >>> publications, starting in 2001, for the inventions covered in <<<

>>> USPATFULL. A USPATFULL record contains not only the original <<<  
 >>> published document but also a list of any subsequent <<<  
 >>> publications. The publication number, patent kind code, and <<<  
 >>> publication date for all the US publications for an invention <<<  
 >>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
 >>> records and may be searched in standard search fields, e.g., /PN, <<<  
 >>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
 >>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
 >>> enter this cluster. <<<

>>> <<<

>>> Use USPATALL when searching terms such as patent assignees, <<<  
 >>> classifications, or claims, that may potentially change from <<<  
 >>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))

1928 INHALANT  
 236 TIOTROPIUM  
 236 TIOTROPIUM  
 145139 BROMIDE  
 133 TIOTROPIUM BROMIDE  
 (TIOTROPIUM(W) BROMIDE)  
 236 TIOTROPIUM  
 145139 BROMIDE  
 156 MONHYDRATE  
 0 TIOTROPIUM BROMIDE MONHYDRATE  
 (TIOTROPIUM(W) BROMIDE(W) MONHYDRATE)

L7 13 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s l7 and (particle# or particulate#)

552872 PARTICLE#  
 156148 PARTICULATE#

L8 9 L7 AND (PARTICLE# OR PARTICULATE#)

=> s l2 and powder?

437594 POWDER?  
 L9 3 L2 AND POWDER?

=> d 19 1-3 ibib abs

L9 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:132947 USPATFULL  
 TITLE: Medical aerosol formulations  
 INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL  
 REPUBLIC OF  
 Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

LINE COUNT: 986

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.

L9 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6235725 B1 20010522

APPLICATION INFO.: US 1999-362540 19990728 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1998-106507P 19981030 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Peselev, Elli

LEGAL REPRESENTATIVE: Levi-Minzi, Simona A.

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β.sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL

TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules

INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States

Saim, Said, New Milford, CT, United States

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6228394 B1 20010508

APPLICATION INFO.: US 1998-157267 19980921 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-62099P 19971014 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Seidleck, Brian K.  
LEGAL REPRESENTATIVE: Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 12 Drawing Page(s)  
LINE COUNT: 1487  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 1-9 ibib abs

L8 ANSWER 1 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2004:132947 USPATFULL  
TITLE: Medical aerosol formulations  
INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	986	
AB	Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.	

L8 ANSWER 2 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2003:283185 USPATFULL  
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders  
INVENTOR(S): Garvey, David S., Dover, MA, UNITED STATES  
Letts, L. Gordon, Dover, MA, UNITED STATES  
Renfroe, H. Burt, Wellesley, MA, UNITED STATES  
Richardson, Stewart K., Ashford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199529	A1	20031023
APPLICATION INFO.:	US 2003-428936	A1	20030505 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-689851, filed on 13 Oct 2000, GRANTED, Pat. No. US 6579863 Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, GRANTED, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, GRANTED, Pat. No. US 5824669 Division of Ser. No. WO 1997-US4319, filed on 19 Mar 1997, PENDING

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 2520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:176162 USPATFULL

TITLE: Medicinal aerosol formulations

INVENTOR(S): Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF

Herzog, Kurt, Basel, SWITZERLAND

Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF

Kraus, Holger, Rickenbach, SWITZERLAND

PATENT ASSIGNEE(S): Jago Research AG, Muttenz, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6585958	B1	20030701
	WO 2000006121		20000210
APPLICATION INFO.:	US 2001-744379		20010413 (9)
	WO 1999-CH337		19990722

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1998-1565	19980724

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Hartley, Michael G.

ASSISTANT EXAMINER: Haghigatian, M.

LEGAL REPRESENTATIVE: Selitto, Behr & Kim

NUMBER OF CLAIMS: 51

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 995

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pressure-liquefied propellant mixture for aerosols, comprising

dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the particle size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:161952 USPATFULL  
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders  
INVENTOR(S): Garvey, David S., Waltham, MA, United States  
Lettis, L. Gordon, Dover, MA, United States  
Renfroe, H. Burt, Wellesley, MA, United States  
Richardson, Stewart K., Ashford, CT, United States  
PATENT ASSIGNEE(S): Nitromed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6579863	B1	20030617
APPLICATION INFO.:	US 2000-689851		20001013 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, now patented, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Badio, Barbara P.

LEGAL REPRESENTATIVE: Hale and Dorr LLP

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)

LINE COUNT: 2028

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a  $\beta$ -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids,  $\beta$ -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL  
TITLE: Methods and compositions for the prevention of tolerance to medications  
INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S) : Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to  $\beta$ .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2001:67205 USPATFULL  
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules  
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States  
Saim, Said, New Milford, CT, United States  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:42141 USPATFULL  
 TITLE: Nitrosated and nitrosylated compounds, and compositions  
 and their use for treating respiratory disorders  
 INVENTOR(S): Garvey, David S., Dover, MA, United States  
 Letts, L. Gordon, Dover, MA, United States  
 Renfroe, H. Burt, Wellesley, MA, United States  
 Richardson, Stewart K., Ashford, CT, United States  
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37116	E1	20010327
	US 5824669		19981020 (Original)
APPLICATION INFO.:	US 1998-219476		19981223 (9)
	US 1996-620882		19960322 (Original)

DOCUMENT TYPE: Reissue  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Rotman, Alan L.  
 LEGAL REPRESENTATIVE: Hale and Dorr LLP  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)  
 LINE COUNT: 1916  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO.circled-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders. ##STR1##  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 9 USPATFULL on STN  
 ACCESSION NUMBER: 2001:33259 USPATFULL  
 TITLE: Nitrosated and nitrosylated steroids compositions, and methods for treating respiratory disorders  
 INVENTOR(S): Garvey, David S., Waltham, MA, United States  
 Letts, L. Gordon, Dover, MA, United States  
 Renfroe, H. Burt, Wellesley, MA, United States  
 Richardson, Stewart K., Ashford, CT, United States  
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197762	B1	20010306
APPLICATION INFO.:	US 1998-157242		19980918 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Desai, Rita		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	16		

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)  
LINE COUNT: 1841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 1998:128257 USPATFULL  
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders  
INVENTOR(S): Garvey, David S., Dover, MA, United States  
Letts, L. Gordon, Dover, MA, United States  
Renfroe, H. Burt, Wellesley, MA, United States  
Richardson, Stewart K., Ashford, CT, United States  
PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824669		19981020
APPLICATION INFO.:	US 1996-620882		19960322 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1812		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>  
Connection closed by remote host

# WEST Search History

DATE: Tuesday, February 04, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L9	L8 and mix\$ and coars\$ and fin\$	4	L9
L8	L7 and (COPD or asthma or respiratory)	22	L8
L7	L6 and (um or micrometer or micron?)	22	L7
L6	L5 and (mean particle size)	52	L6
L5	L4 and (glucose or arabinose or lactose or saccharose or maltose or dextrane or sorbitol or mannitol or xylitol or (sodium chloride) or (calcium carbonate))	52	L5
L4	L3 and (average particle size)	62	L4
L3	L2 and (chloride or bromide or iodide or metjhnaesulphonate or paratoluenesulphonate or (methyl sulphate))	71	L3
L2	L1 and Tiotropium	78	L2
L1	inhal\$ and (powder\$ or partic\$ or pellet\$)	33911	L1

END OF SEARCH HISTORY

	Image Doc. Displayed	PT
1	US 20020122826	<input type="checkbox"/>
2	US 20020111495	<input type="checkbox"/>

	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1		Lizio, Rosario et al.	<input type="checkbox"/>						
2		Magee, Thomas Victor et al.	<input type="checkbox"/>						

	U	1	Document ID	Issue Date	Pages
1	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020122826 A1	20020905	11
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020111495 A1	20020815	155

	Title	Current OR	Current XRef
1	Solid peptide preparations for inhalation and their preparation	424/489	241/18
2	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes	546/291	546/298; 546/315

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
                  saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
                  now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
                  ENERGY, INSPEC

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau153cxa

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated and searchable  
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in CA/CAplus  
NEWS 5 FEB 05 German (DE) application and patent publication number format changes  
NEWS 6 MAR 03 MEDLINE and LMEDLINE reloaded  
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 8 MAR 03 FRANCEPAT now available on STN  
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN  
NEWS 10 MAR 29 WPIFV now available on STN  
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA  
NEWS 12 APR 26 PROMT: New display field available  
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field available  
NEWS 14 APR 26 LITALERT now available on STN  
NEWS 15 APR 27 NLDB: New search and display fields available  
NEWS 16 May 10 PROUSDDR now available on STN  
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May and June 2004  
NEWS 18 May 12 EXTEND option available in structure searching  
.NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY  
NEWS 20 May 17 FRFULL now available on STN  
NEWS 21 May 27 STN User Update to be held June 7 and June 8 at the SLA 2004 Conference  
NEWS 22 May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus  
NEWS 23 May 27 CAplus super roles and document types searchable in REGISTRY  
NEWS 24 May 27 Explore APOLLIT with free connect time in June 2004  
  
NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004

=> le caplus uspatful europatful jatio medline biosis embase  
LE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus uspatful europatful japiro medline biosis embase  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 16:10:45 ON 10 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'MEDLINE' ENTERED AT 16:10:45 ON 10 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:10:45 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))  
L1 60 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s 11 and (particle# or particulate#)  
L2 29 L1 AND (PARTICLE# OR PARTICULATE#)

=> s 12 and powder?  
L3 19 L2 AND POWDER?

=> s 13 and capsule?  
L4 13 L3 AND CAPSULE?

=> s l4 and (COPD or asthma)  
L5 5 L4 AND (COPD OR ASTHMA)

=> s 15 and (method or process) and (making or preparation or manufacture)  
6 FILES SEARCHED...

L6 2 LS AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MANUFACTURE)

=> d 16 1-2 IBIB ABA  
'ABA' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT) :ABS

NO VALID FORMATS ENTERED FOR FILE 'EUROPATFULL'

In a multifile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT) :AB

L6 ANSWER 1 OF 2 USPATFULL on STN

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β.sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> S

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END) :L6 ibib ab

MISSING OPERATOR L6 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d 16 1-2 IBIB AB

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Peselev, Elli

LEGAL REPRESENTATIVE: Levi-Minzi, Simona A.

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β.sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS  
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.  
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.  
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.  
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;  
YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP  
PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP  
PATENT ASSIGNEE NO: 435424  
AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675 Muenchen, DE  
AGENT NUMBER: 100401  
OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322  
SOURCE: Wila-EPZ-2004-H20-T1b  
DOCUMENT TYPE: Patent  
LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;  
Verfahren in Englisch  
DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI  
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)  
PATENT INFORMATION:

PATENT NO	KIND DATE
EP 1417975	A1 20040512 20040512
APPLICATION INFO.:	EP 2002-747707 20020722

PRIORITY APPLN. INFO.: JP 2001-2001222148 20010723  
                   JP 2001-2001239895 20010807  
                   JP 2002-2002056449 20020301  
 RELATED DOC. INFO.: WO 02-JP7385 020722 INTAKZ  
                   WO 2003009872 030206 INTPNR

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'  
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1       60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE))  
 L2       29 S L1 AND (PARTICLE# OR PARTICULATE#)  
 L3       19 S L2 AND POWDER?  
 L4       13 S L3 AND CAPSULE?  
 L5       5 S L4 AND (COPD OR ASTHMA)  
 L6       2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MANUFACTURE)

=> d 15 1-5

L5       ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN      2003:757705 CAPLUS  
 DN      139:265796  
 TI      Preparation of micronized crystalline tiotropium bromide monohydrate and formulation as inhalant to treat asthma and COPD  
 IN      Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef Friedrich; Walz, Michael  
 PA      Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany  
 SO      PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2

DT      Patent  
 LA      German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10212264	A1	20031002	DE 2002-10212264	20020320
	US 2004002510	A1	20040101	US 2003-385175	20030310
PRAI	DE 2002-10212264	A	20020320		
	US 2002-413129P	P	20020924		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:368320 CAPLUS  
DN 136:374855  
TI Inhalant compositions containing tiotropium salts and salmeterol salts  
IN Schmelzer, Christel; Nagel, Juergen  
PA Boehringer Ingelheim Pharma K.-G., Germany  
SO PCT Int. Appl., 36 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512
PRAI DE 2000-10056104	A	20001113		
US 2000-251603P	P	20001206		
WO 2001-EP12962	W	20011109		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:689613 CAPLUS  
DN 136:390861  
TI Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity  
AU Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.  
CS Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA  
SO Journal of Aerosol Medicine (2001), 14(3), 309-315  
CODEN: JAEMEP; ISSN: 0894-2684  
PB Mary Ann Liebert, Inc.  
DT Journal  
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 USPATFULL on STN  
AN 2001:75378 USPATFULL  
TI Methods and compositions for the prevention of tolerance to medications  
IN Ahmed, Tahir, Coral Gables, FL, United States

PA Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S.  
 corporation)  
 PI US 6235725 B1 20010522  
 AI US 1999-362540 19990728 (9)  
 PRAI US 1998-106507P 19981030 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 985  
 INCL INCLM: 514/056.000  
 INCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000  
 NCL NCLM: 514/056.000  
 NCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000  
 IC [7]  
 ICM: A61K031-70  
 EXF 514/53; 514/54; 514/56; 514/653; 514/826; 514/23  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1417975 EUROPATFULL ED 20040513 EW 200420 FS OS  
 TIEN REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE  
 ACTIVE INGREDIENT.  
 TIDE MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND  
 EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.  
 TIFR MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF  
 DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.  
 IN MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai  
 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;  
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1,  
 Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai  
 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai  
 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP  
 PA ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku,  
 Osaka-shi, Osaka 541-8526, JP  
 SO Wila-EPZ-2004-H20-T1b  
 DS R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR;  
 R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR;  
 R AL; R LT; R LV; R MK; R RO; R SI  
 PIT EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale Anmeldung)  
 PI EP 1417975 A1 20040512  
 OD 20040512  
 AI EP 2002-747707 20020722  
 PRAI JP 2001-2001222148 20010723  
 JP 2001-2001239895 20010807  
 JP 2002-2002056449 20020301  
 RLI WO 02-JP7385 020722 INTAKZ  
 WO 2003009872 030206 INTPNR  
 IC ICM A61K045-00  
 ICS A61K031-559 C07D207-24 C07D207-27 C07D263-24  
 C07C405-00 A61P019-08 A61P019-10

=> FILE STNGUIDE  
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

65.21

65.42

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jun 4, 2004 (20040604/UP).

=> file caplus uspatfull japiro europaftul biosis embase medline  
'EUROPAFTUL' IS NOT A VALID FILE NAME  
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files  
that are available. If you have requested multiple files, you can  
specify a corrected file name or you can enter "IGNORE" to continue  
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):europatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.66	66.08

FILE 'CAPLUS' ENTERED AT 16:28:44 ON 10 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'EUROPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:28:44 ON 10 JUN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:28:44 ON 10 JUN 2004

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'  
ENTERED AT 16:10:45 ON 10 JUN 2004  
L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI  
L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)  
L3 19 S L2 AND POWDER?  
L4 13 S L3 AND CAPSULE?  
L5 5 S L4 AND (COPD OR ASTHMA)  
L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'  
ENTERED AT 16:28:44 ON 10 JUN 2004

=> s 14 1-13

MISSING OPERATOR L4 1-13

The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> d 14 1-13 ibib abs

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2003:757705 CAPLUS  
DOCUMENT NUMBER: 139:265796  
TITLE: Preparation of micronized crystalline tiotropium bromide monohydrate and formulation as inhalant to treat asthma and COPD  
INVENTOR(S): Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef Friedrich; Walz, Michael  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany  
SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10212264	A1	20031002	DE 2002-10212264	20020320
US 2004002510	A1	20040101	US 2003-385175	20030310
PRIORITY APPLN. INFO.:			DE 2002-10212264 A	20020320
			US 2002-413129P	P 20020924

AB The invention relates to a micronized crystalline (1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0<sub>2,4</sub>]nonane bromide, methods for the production thereof, and the use thereof for producing a medicament, particularly for producing a medicament having an anticholinergic effect. The preparation of tiotropium bromide monohydrate microcrystals includes the solution of tiotropium bromide in water, heating, clarification with active carbon, filtration and slow crystallization followed

by micronization in an air jet mill under nitrogen atmospheric and exposing the micronized crystals to water vapor. Parameters of the monocline crystals are given. Micronized crystalline tiotropium bromide monohydrate is formulated to encapsulated inhalation powder and used to treat asthma and COPD. Thus inhalation capsules contained (mg): micronized tiotropium bromide 0.0225; lactose monohydrate (200 M) 5.2025; lactose monohydrate (5 μm) 0.2750; hard gelatin capsules 49.0.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:889143 CAPLUS  
DOCUMENT NUMBER: 137:358198  
TITLE: Stable powder inhalation dosage formulation  
INVENTOR(S): Etzler, Frank M.  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA  
SOURCE: U.S., 6 pp.

CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482429	B1	20021119	US 2001-885349	20010620
WO 2003000240	A2	20030103	WO 2002-US18406	20020611
WO 2003000240	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1401409	A2	20040331	EP 2002-732063	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-885349 A 20010620  
WO 2002-US18406 W 20020611

AB An insufflation for the administration of a drug, e.g., ipratropium bromide, albuterol sulfate or **tiotropium bromide**, into a body cavity is described where the carrier for the drug is a finely divided powder selected from the group consisting of myoinositol, mannitol and cellobiose. For example, the cellobiose blend with ipratropium bromide which was inhaled from capsules into Aerobreather at 20, 40 and 60 L/min has a lower mean particle size than the lactose blend, which is the opposite of the particle sizing results from the Aerosizer. The peaks of the distributions for the cellobiose blend were shifted to lower particle sizes than the lactose blend at all inhalation rates. The difference could reflect differences in adhesion strength, particle size distribution or size selection of retained particles.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:695761 CAPLUS  
 DOCUMENT NUMBER: 137:237718  
 TITLE: Inhalant compositions containing anticholinergics and PDE IV inhibitors  
 INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel;  
 Pieper, Michael Paul  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069945	A2	20020912	WO 2002-EP1988	20020226
WO 2002069945	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10110772 A1 20020912 DE 2001-10110772 20010307

EP 1372649 A2 20040102 EP 2002-727329 20020226

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: DE 2001-10110772 A 20010307  
WO 2002-EP1988 W 20020226

OTHER SOURCE(S): MARPAT 137:237718

AB The invention relates to drug compns. based on anticholinergics and PDE IV inhibitors, to methods for their production, and to their use as inhalants for the treatment of respiratory tract diseases. Thus an inhalation powder was composed of capsules that contained ( $\mu$ g/capsule): tiotropium bromide 21.7; AWD-12-281 200; lactose 4778.3.

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:487380 CAPLUS

DOCUMENT NUMBER: 137:68157

TITLE: Inhalant compositions containing

INVENTOR(S): anticholinergics and dopamine agonists  
Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049624	A2	20020627	WO 2001-EP14568	20011212
WO 2002049624	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10063957	A1	20020627	DE 2000-10063957	20001220
AU 2002035767	A5	20020701	AU 2002-35767	20011212
EP 1345626	A2	20030924	EP 2001-985868	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004516264	T2	20040603	JP 2002-550966	20011212
US 2002122773	A1	20020905	US 2001-27662	20011220
PRIORITY APPLN. INFO.:			DE 2000-10063957 A	20001220
			US 2000-257221P P	20001221
			WO 2001-EP14568 W	20011212

AB The invention relates to novel pharmaceutical compns. based on anticholinergic agents and dopamine agonists, a method for the production of the compns. and the use of the same for the treatment of respiratory tract diseases. Thus an inhalation powder contained per capsule ( $\mu$ g): tiotropium bromide 21.7;  
viozan 270; lactose 4708.3.

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:465799 CAPLUS  
 DOCUMENT NUMBER: 137:37667  
 TITLE: Inhalant compositions containing  
 anticholinergics and ciclesonide corticosteroid  
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,  
 Christopher John Montague  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047668	A2	20020620	WO 2001-EP14579	20011212
WO 2002047668	A3	20020829		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002031691	A5	20020624	AU 2002-31691	20011212
EP 1349549	A2	20031008	EP 2001-991827	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004515528	T2	20040527	JP 2002-549242	20011212
PRIORITY APPLN. INFO.:			DE 2000-10062712 A	20001215
			DE 2000-10054042 A	20001031
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			WO 2001-EP14579 W	20011212

AB The invention relates to novel medicament compns. based on  
 anticholinesterase drugs and on ST-126, to methods for their production, and  
 to their use in treating respiratory tract diseases. Thus an inhalation  
 powder contained per capsule ( $\mu$ g): tiotropium  
 bromide x H<sub>2</sub>O 22.5; ciclesonide 250; lactose 4727.5.

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:465798 CAPLUS  
 DOCUMENT NUMBER: 137:52368  
 TITLE: Inhalant compositions containing  
 anticholinergics and ST-126 corticosteroid  
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,  
 Christopher John Montague  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047667	A2	20020620	WO 2001-EP14567	20011212
WO 2002047667	A3	20021024		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10062712 A1 20020620 DE 2000-10062712 20001215

US 2002183292 A1 20021205 US 2001-86145 20011019

AU 2002024926 A5 20020624 AU 2002-24926 20011212

PRIORITY APPLN. INFO.:

DE 2000-10062712 A 20001215

DE 2000-10054042 A 20001031

US 2000-253613P P 20001128

US 2000-257220P P 20001221

WO 2001-EP14567 W 20011212

AB The invention relates to novel medicament compns. based on anticholinesterase drugs and on ST-126 corticosteroid, to methods for their production, and to their use in treating respiratory tract diseases. Thus an inhalation powder contained per capsule ( $\mu$ g): tiotropium bromide x H<sub>2</sub>O 22.5; ST-126 250; lactose 4727.5.

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:368320 CAPLUS

DOCUMENT NUMBER: 136:374855

TITLE: Inhalant compositions containing

tiotropium salts and salmeterol salts

INVENTOR(S): Schmelzer, Christel; Nagel, Juergen

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512

PRIORITY APPLN. INFO.:

DE 2000-10056104 A 20001113

US 2000-251603P P 20001206

WO 2001-EP12962 W 20011109

AB The invention relates to novel drug compns. based on tiotropium

salts and on salmeterol salts, a method for their production and their use for treating respiratory conditions. Thus an inhalation powder contained per capsule ( $\mu\text{g}$ ): **tiotropium bromide** 10.8; salmeterol x 1/2 H<sub>2</sub>SO<sub>4</sub> 27.9; Lactose 4961.3.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:353268 CAPLUS  
DOCUMENT NUMBER: 136:374832  
TITLE: **Inhalant compositions containing anticholinergics and corticosteroids**  
INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Reichl, Richard; Schmelzer, Christel  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
SOURCE: PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036106	A2	20020510	WO 2001-EP12511	20011023
WO 2002036106	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002151541	A1	20021017	US 2001-7182	20011019
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002010575	A5	20020515	AU 2002-10575	20011023
EP 1333830	A2	20030813	EP 2001-978463	20011023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004512359	T2	20040422	JP 2002-538918	20011023
US 2002137764	A1	20020926	US 2001-40196	20011025
US 2003181478	A1	20030925	US 2003-395777	20030324
PRIORITY APPLN. INFO.:			DE 2000-10054042 A	20001031
			DE 2000-10062712 A	20001215
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			DE 2001-10138272 A	20010810
			US 2001-314599P P	20010824
			WO 2001-EP12511 W	20011023
			US 2001-40196 B1	20011025

AB The invention relates to novel drug compns. based on anticholinergics and corticosteroids, a method for their production and their use for treating respiratory conditions. Thus an inhalation powder contained per capsule ( $\mu\text{g}$ ): **tiotropium bromide** 21.7; budesonide 200; Lactose 4778.3.

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2001:689613 CAPLUS  
DOCUMENT NUMBER: 136:390861  
TITLE: **Effective delivery of particles with the HandiHaler dry powder inhalation system over**

AUTHOR(S): a range of chronic obstructive pulmonary disease severity  
Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven;  
Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.

CORPORATE SOURCE: Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA

SOURCE: Journal of Aerosol Medicine (2001), 14(3), 309-315  
CODEN: JAEMEP; ISSN: 0894-2684

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The HandiHaler is a dry powder breath activated inhaler system developed for inhalation therapy for patients with airway disease. Its operation is based on the evacuation of powder from a pierced capsule. We sought to document the inspiratory flow rates attained by patients inspiring through the HandiHaler with various degrees of airflow limitation. Subjects with stable chronic obstructive pulmonary disease (COPD) were the study's population. An in vitro study of fine particle dose was conducted using an Andersen Cascade Impactor to assess medication delivery at low inspiratory flow rates. Subsequently, an in vivo study was conducted to determine inspiratory flow rates in patients with COPD as measured through a pneumotach with a custom coupler device with and without the HandiHaler. Patients were classified into three approx. equal groups of spirometric severity ranging from mild (46-65% predicted normal forced expiratory volume in 1 s [FEV1]), to moderate (28-45%) to severe (<27%). The in vitro study indicated delivery of medication at flow rates as low as 20 L/min. Twenty-six men completed the in vivo study (age  $66.9 \pm 10.9$  yr, FEV1 =  $1.02 \pm 0.451$ ). The median peak inspiratory flow rates attained in the mild (n = 8), moderate (n = 10), and severe (n = 8) categories were 45, 45.6, and 35.4 L/min resp. The min. peak inspiratory flow rates in the three groups were 28.2, 21.6 and 20.4 L/min. The HandiHaler device effectively delivers particles to the lung over a wide range of airflow limitation in patients with COPD.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2001:75378 USPATFULL  
TITLE: Methods and compositions for the prevention of tolerance to medications  
INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States  
PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators.

More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to  $\beta$ .<sub>2</sub>-adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2001:67205 USPATFULL  
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules  
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States  
Saim, Said, New Milford, CT, United States  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS  
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.  
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.  
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.  
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;  
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co.,

Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun,  
 Osaka 618-8585, JP;  
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co.,  
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,  
 Osaka 618-8585, JP;  
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co.,  
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,  
 Osaka 618-8585, JP;  
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co.,  
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,  
 Osaka 618-8585, JP  
**PATENT ASSIGNEE(S) :** ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome,  
 Chuo-ku, Osaka-shi, Osaka 541-8526, JP  
**PATENT ASSIGNEE NO:** 435424  
**AGENT:** Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675  
 Muenchen, DE  
**AGENT NUMBER:** 100401  
**OTHER SOURCE:** MEPA2004039 EP 1417975 A1 0322  
**SOURCE:** Wila-EPZ-2004-H20-T1b  
**DOCUMENT TYPE:** Patent  
**LANGUAGE:** Anmeldung in Japanisch; Veroeffentlichung in Englisch;  
 Verfahren in Englisch  
**DESIGNATED STATES:** R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R  
 ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R  
 MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R  
 MK; R RO; R SI  
**PATENT INFO. PUB. TYPE:** EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale  
 Anmeldung)  
**PATENT INFORMATION:**

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1417975	A1 20040512
APPLICATION INFO.:	EP 2002-747707	20020722
PRIORITY APPLN. INFO.:	JP 2001-2001222148	20010723
	JP 2001-2001239895	20010807
	JP 2002-2002056449	20020301
RELATED DOC. INFO.:	WO 02-JP7385	020722 INTAKZ
	WO 2003009872	030206 INTPNR

L4 ANSWER 13 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

**PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET**

**ACCESSION NUMBER:** 1391200 EUROPATFULL EW 200409 FS OS  
**TITLE:** DRUG PREPARATIONS.  
 ARZNEIMITTEL.  
 PREPARATIONS DE MEDICAMENTS.  
**INVENTOR(S) :** ONUKI, Yoichi, 2-31-7, Nakadai, Narita-shi, Chiba  
 286-0015, JP;  
 OKADA, Minoru, 4-7-20, Kioroshihigashi, Inzai-shi, Chiba  
 270-1323, JP;  
 SAKAI, Hirotaka, 1-20-6, Yotsukaido, Yotsukaido-shi,  
 Chiba 284-0005, JP;  
 KANBE, Hideyoshi, 2-21-8, Mama, Ichikawa-shi, Chiba  
 272-0826, JP;  
 MIZUNO, Hiroyuki, 1-24-19, Hiyoshidai, Tomisato-machi,  
 Inba-gun, Chiba 286-0201, JP;  
 IMAMORI, Katsumi, 2521-86, Shimoshizushinden,  
 Yotsukaido-shi, Chiba 284-0006, JP  
**PATENT ASSIGNEE(S) :** SSP Co., Ltd., 12-4, Nihonbashi-hamacho 2-chome,  
 Chuo-ku, Tokyo 103-8481, JP  
**PATENT ASSIGNEE NO:** 2557581  
**AGENT:** Hartz, Nikolai, Waechtershaeuser & Hartz,  
 Patentanwaelte, Weinstrasse 8, 80333 Muenchen, DE

AGENT NUMBER: 85663  
 OTHER SOURCE: MEPA2004017 EP 1391200 A1 0014  
 SOURCE: Wila-EPZ-2004-H09-T1b  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;  
 Verfahren in Englisch  
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R  
 GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R  
 SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI  
 PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale  
 Anmeldung)  
 PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1391200	A1 20040225
APPLICATION INFO.:	EP 2002-726486	20020524
PRIORITY APPLN. INFO.:	JP 2001-2001156853	20010525
RELATED DOC. INFO.:	WO 200JP2005041	020524 INTAKZ
	WO 2002096405	021205 INTPNR

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'  
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1	60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2	29 S L1 AND (PARTICLE# OR PARTICULATE#)
L3	19 S L2 AND POWDER?
L4	13 S L3 AND CAPSULE?
L5	5 S L4 AND (COPD OR ASTHMA)
L6	2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'  
 ENTERED AT 16:28:44 ON 10 JUN 2004

=> file uspatful		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	63.51	129.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'USPATFULL' ENTERED AT 16:45:49 ON 10 JUN 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Jun 2004 (20040610/PD)  
 FILE LAST UPDATED: 10 Jun 2004 (20040610/ED)  
 HIGHEST GRANTED PATENT NUMBER: US6748598  
 HIGHEST APPLICATION PUBLICATION NUMBER: US2004111778  
 CA INDEXING IS CURRENT THROUGH 10 Jun 2004 (20040610/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Jun 2004 (20040610/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
 >>> original, i.e., the earliest published granted patents or <<<  
 >>> applications. USPAT2 contains full text of the latest US <<<  
 >>> publications, starting in 2001, for the inventions covered in <<<

>>> USPATFULL. A USPATFULL record contains not only the original <<<  
 >>> published document but also a list of any subsequent <<<  
 >>> publications. The publication number, patent kind code, and <<<  
 >>> publication date for all the US publications for an invention <<<  
 >>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
 >>> records and may be searched in standard search fields, e.g., /PN, <<<  
 >>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
 >>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
 >>> enter this cluster. <<<

>>> <<<  
 >>> Use USPATALL when searching terms such as patent assignees, <<<  
 >>> classifications, or claims, that may potentially change from <<<  
 >>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))

1928 INHALANT  
 236 TIOTROPIUM  
 236 TIOTROPIUM  
 145139 BROMIDE  
 133 TIOTROPIUM BROMIDE  
 (TIOTROPIUM(W) BROMIDE)  
 236 TIOTROPIUM  
 145139 BROMIDE  
 156 MONHYDRATE  
 0 TIOTROPIUM BROMIDE MONHYDRATE  
 (TIOTROPIUM(W) BROMIDE(W) MONHYDRATE)

L7 13 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s l7 and (particle# or particulate#)

552872 PARTICLE#  
 156148 PARTICULATE#

L8 9 L7 AND (PARTICLE# OR PARTICULATE#)

=> s l2 and powder?

437594 POWDER?  
 L9 3 L2 AND POWDER?

=> d 19 1-3 ibib abs

L9 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:132947 USPATFULL  
 TITLE: Medical aerosol formulations  
 INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL  
 REPUBLIC OF  
 Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

LINE COUNT: 986

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.

L9 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6235725 B1 20010522

APPLICATION INFO.: US 1999-362540 19990728 (9)

NUMBER DATE

PRIORITY INFORMATION: US 1998-106507P 19981030 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Peselev, Elli

LEGAL REPRESENTATIVE: Levi-Minzi, Simona A.

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β.sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL

TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules

INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States

Saim, Said, New Milford, CT, United States

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6228394 B1 20010508

APPLICATION INFO.: US 1998-157267 19980921 (9)

NUMBER DATE

PRIORITY INFORMATION: US 1997-62099P 19971014 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Seidleck, Brian K.  
LEGAL REPRESENTATIVE: Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 12 Drawing Page(s)  
LINE COUNT: 1487  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 1-9 ibib abs

L8 ANSWER 1 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2004:132947 USPATFULL  
TITLE: Medical aerosol formulations  
INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	986	
AB	Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.	

L8 ANSWER 2 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2003:283185 USPATFULL  
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders  
INVENTOR(S): Garvey, David S., Dover, MA, UNITED STATES  
Letts, L. Gordon, Dover, MA, UNITED STATES  
Renfroe, H. Burt, Wellesley, MA, UNITED STATES  
Richardson, Stewart K., Ashford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199529	A1	20031023
APPLICATION INFO.:	US 2003-428936	A1	20030505 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-689851, filed on 13 Oct 2000, GRANTED, Pat. No. US 6579863 Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, GRANTED, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, GRANTED, Pat. No. US 5824669 Division of Ser. No. WO 1997-US4319, filed on 19 Mar 1997, PENDING

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 2520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:176162 USPATFULL

TITLE: Medicinal aerosol formulations

INVENTOR(S): Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF

Herzog, Kurt, Basel, SWITZERLAND

Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF

Kraus, Holger, Rickenbach, SWITZERLAND

PATENT ASSIGNEE(S): Jago Research AG, Muttenz, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6585958	B1	20030701
	WO 2000006121		20000210
APPLICATION INFO.:	US 2001-744379		20010413 (9)
	WO 1999-CH337		19990722

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1998-1565	19980724

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Hartley, Michael G.

ASSISTANT EXAMINER: Haghighatian, M.

LEGAL REPRESENTATIVE: Selitto, Behr & Kim

NUMBER OF CLAIMS: 51

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 995

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pressure-liquefied propellant mixture for aerosols, comprising

dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the particle size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:161952 USPATFULL

TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders

INVENTOR(S): Garvey, David S., Waltham, MA, United States  
Letts, L. Gordon, Dover, MA, United States

Renfroe, H. Burt, Wellesley, MA, United States

Richardson, Stewart K., Ashford, CT, United States

PATENT ASSIGNEE(S): Nitromed, Inc., Bedford, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----

PATENT INFORMATION: US 6579863 B1 20030617

APPLICATION INFO.: US 2000-689851 20001013 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, now patented, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Badio, Barbara P.

LEGAL REPRESENTATIVE: Hale and Dorr LLP

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)

LINE COUNT: 2028

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a  $\beta$ -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids,  $\beta$ -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S) : Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

NUMBER      KIND      DATE

PATENT INFORMATION: US 6235725      B1      20010522  
APPLICATION INFO.: US 1999-362540      19990728 (9)

NUMBER      DATE

PRIORITY INFORMATION: US 1998-106507P      19981030 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Peselev, Elli  
LEGAL REPRESENTATIVE: Levi-Minzi, Simona A.  
NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)  
LINE COUNT: 985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to  $\beta$ .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL  
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules  
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States  
              Saim, Said, New Milford, CT, United States  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

NUMBER      KIND      DATE

PATENT INFORMATION: US 6228394      B1      20010508  
APPLICATION INFO.: US 1998-157267      19980921 (9)

NUMBER      DATE

PRIORITY INFORMATION: US 1997-62099P      19971014 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Seidleck, Brian K.  
LEGAL REPRESENTATIVE: Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 12 Drawing Page(s)  
LINE COUNT: 1487

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:42141 USPATFULL  
 TITLE: Nitrosated and nitrosylated compounds, and compositions  
 and their use for treating respiratory disorders  
 INVENTOR(S): Garvey, David S., Dover, MA, United States  
 Letts, L. Gordon, Dover, MA, United States  
 Renfroe, H. Burt, Wellesley, MA, United States  
 Richardson, Stewart K., Ashford, CT, United States  
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37116	E1	20010327
	US 5824669		19981020 (Original)
APPLICATION INFO.:	US 1998-219476		19981223 (9)
	US 1996-620882		19960322 (Original)

DOCUMENT TYPE: Reissue  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Rotman, Alan L.  
 LEGAL REPRESENTATIVE: Hale and Dorr LLP  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)  
 LINE COUNT: 1916  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

**AB** Disclosed are (i) compounds of a steroid, a  $\beta$ -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids,  $\beta$ -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO.circled-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders. ##STR1###

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 9 USPATFULL on STN  
 ACCESSION NUMBER: 2001:33259 USPATFULL  
 TITLE: Nitrosated and nitrosylated steroids compositions, and methods for treating respiratory disorders  
 INVENTOR(S): Garvey, David S., Waltham, MA, United States  
 Letts, L. Gordon, Dover, MA, United States  
 Renfroe, H. Burt, Wellesley, MA, United States  
 Richardson, Stewart K., Ashford, CT, United States  
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197762	B1	20010306
APPLICATION INFO.:	US 1998-157242		19980918 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Desai, Rita		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	16		

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)  
LINE COUNT: 1841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a  $\beta$ -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids,  $\beta$ -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 1998:128257 USPATFULL  
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders  
INVENTOR(S): Garvey, David S., Dover, MA, United States  
Lettts, L. Gordon, Dover, MA, United States  
Renfroe, H. Burt, Wellesley, MA, United States  
Richardson, Stewart K., Ashford, CT, United States  
PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824669		19981020
APPLICATION INFO.:	US 1996-620882		19960322 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1812		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a  $\beta$ -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO<sub>2</sub> group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids,  $\beta$ -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>.</sup>) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>  
Connection closed by remote host